{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:09:30Z","timestamp":1789362570839,"version":"build-2803163510"},"reference-count":59,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01ZX1310C"],"award-info":[{"award-number":["01ZX1310C"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["0315890A"],"award-info":[{"award-number":["0315890A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01ZX1308B"],"award-info":[{"award-number":["01ZX1308B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004412","name":"Human Frontier Science Program","doi-asserted-by":"publisher","award":["RGP0033\/2015"],"award-info":[{"award-number":["RGP0033\/2015"]}],"id":[{"id":"10.13039\/100004412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB854"],"award-info":[{"award-number":["SFB854"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"DOI":"10.3389\/fcimb.2016.00060","type":"journal-article","created":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T03:36:34Z","timestamp":1465875394000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["Oseltamivir PK\/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection"],"prefix":"10.3389","volume":"6","author":[{"given":"Alessandro","family":"Boianelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niharika","family":"Sharma-Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunja","family":"Bruder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban A.","family":"Hernandez-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2016,6,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/jac\/dkg007","article-title":"Early administration of oral oseltamivir increases the benefits of influenza treatment","volume":"51","author":"Aoki","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"7590","DOI":"10.1128\/JVI.01623-05","article-title":"Kinetics of influenza A virus infection in humans","volume":"80","author":"Baccam","year":"2006","journal-title":"J. Virol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1186\/1471-2458-11-S1-S7","article-title":"A review of mathematical models of influenza A infections within a host or cell culture: lessons learned and challenges ahead","volume":"11","author":"Beauchemin","year":"2011","journal-title":"BMC Public Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.3390\/v7102875","article-title":"Modeling influenza virus infection: a roadmap for influenza research","volume":"7","author":"Boianelli","year":"2015","journal-title":"Viruses"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1128\/JVI.01318-10","article-title":"Population modeling of influenza A\/H1N1 virus kinetics and symptom dynamics","volume":"85","author":"Canini","year":"2011","journal-title":"J. Virol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1003568","DOI":"10.1371\/journal.pcbi.1003568","article-title":"Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study","volume":"10","author":"Canini","year":"2014","journal-title":"PLoS Comput. Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10928-014-9363-3","article-title":"Viral kinetic modeling: state of the art","volume":"41","author":"Canini","year":"2014","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"B8","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1093\/infdis\/jiq124","article-title":"Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patientsnorth carolina, 2009","volume":"203","author":"Chen","year":"2011","journal-title":"J. Infect. Diseases"},{"key":"B9","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jtbi.2010.10.017","article-title":"Neuraminidase inhibitors for treatment of human and avian strain influenza: a comparative modeling study","volume":"269","author":"Dobrovolny","year":"2011","journal-title":"J. Theoret. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e57088","DOI":"10.1371\/journal.pone.0057088","article-title":"Assessing mathematical models of influenza infections using features of the immune response","volume":"8","author":"Dobrovolny","year":"2013","journal-title":"PLoS ONE"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/S1473-3099(14)70821-7","article-title":"Antiviral combinations for severe influenza","volume":"14","author":"Dunning","year":"2014","journal-title":"Lancet Infect. Diseases"},{"key":"B12","doi-asserted-by":"publisher","first-page":"RRN1122","DOI":"10.1371\/currents.RRN1122","article-title":"Antiviral usage for H1N1 treatment: pros, cons and an argument for broader prescribing guidelines in the united states","volume":"1","author":"Goldstein","year":"2009","journal-title":"PLoS Curr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"8042","DOI":"10.1128\/JVI.00689-10","article-title":"Competitive fitness of oseltamivir-sensitive and-resistant highly pathogenic H5N1 influenza viruses in a ferret model","volume":"84","author":"Govorkova","year":"2010","journal-title":"J. Virol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1128\/AAC.45.12.3403-3408.2001","article-title":"Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants","volume":"45","author":"Gubareva","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jmb.2011.04.016","article-title":"Structural basis for Streptococcus pneumoniae nana inhibition by influenza antivirals zanamivir and oseltamivir carboxylate","volume":"409","author":"Gut","year":"2011","journal-title":"J. Molecul. Biol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jtbi.2006.12.015","article-title":"A dynamical model of human immune response to influenza A virus infection","volume":"246","author":"Hancioglu","year":"2007","journal-title":"J. Theoret. Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1371\/journal.pcbi.0030240","article-title":"Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread","volume":"3","author":"Handel","year":"2007","journal-title":"PLoS Comput. Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1098\/rstb.2001.1007","article-title":"Perspectives on antiviral use during pandemic influenza","volume":"356","author":"Hayden","year":"2001","journal-title":"Philos. Trans. R Soc. Lond. B Biol. Sci."},{"key":"B19","first-page":"29","article-title":"Innate immune system dynamics to influenza virus","volume-title":"Proceedings of the 8th IFAC Symposium on Biological and Medical Systems","author":"Hernandez-Vargas","year":"2012"},{"key":"B20","doi-asserted-by":"publisher","first-page":"4123","DOI":"10.1128\/JVI.03644-13","article-title":"Effects of aging on influenza virus infection dynamics","volume":"88","author":"Hernandez-Vargas","year":"2014","journal-title":"J. Virol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1353\/bhm.2002.0022","article-title":"Updating the accounts: global mortality of the 1918-1920 \u201cspanish\u201d influenza pandemic","volume":"76","author":"Johnson","year":"2002","journal-title":"Bull. Hist. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5388","DOI":"10.1128\/AAC.00069-15","article-title":"A drug-disease model describing the effect of oseltamivir neuraminidase inhibition on influenza virus progression","volume":"59","author":"Kamal","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1086\/596051","article-title":"Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza","volume":"199","author":"Karlstr\u00f6m","year":"2009","journal-title":"J. Infect. Diseases"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e00172","DOI":"10.1128\/mBio.00172-11","article-title":"Lethal synergism of 2009 pandemic H1N1 influenza virus and Streptococcus pneumoniae coinfection is associated with loss of murine lung repair responses","volume":"2","author":"Kash","year":"2011","journal-title":"MBio"},{"key":"B25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3201\/eid1201.051254","article-title":"Influenza pandemics of the 20th century","volume":"12","author":"Kilbourne","year":"2006","journal-title":"Emerging Infect. Diseases"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mbs.2014.07.006","article-title":"A pharma perspective on the systems medicine and pharmacology of inflammation","volume":"260","author":"Lahoz-Beneytez","year":"2015","journal-title":"Mathemat. Biosci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.1128\/JVI.00098-09","article-title":"Simulation and prediction of the adaptive immune response to influenza a virus infection","volume":"83","author":"Lee","year":"2009","journal-title":"J. Virol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"12304","DOI":"10.1128\/JVI.01269-12","article-title":"Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of \u03b3\u03b4 T cells","volume":"86","author":"Li","year":"2012","journal-title":"J. Virol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1093\/cid\/cis636","article-title":"Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1) pdm09","volume":"55","author":"Louie","year":"2012","journal-title":"Clin. Infect. Diseases"},{"key":"B30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1172\/JCI103791","article-title":"Studies on influenza in the pandemic of 1957-1958. II. pulmonary complications of influenza.","author":"Louria","year":"1959","journal-title":"J. Clin. Invest."},{"key":"B31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1086\/421525","article-title":"Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza","volume":"190","author":"McCullers","year":"2004","journal-title":"J. Infect. Diseases"},{"key":"B33","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1128\/CMR.00058-05","article-title":"Insights into the interaction between influenza virus and pneumococcus","volume":"19","author":"McCullers","year":"2006","journal-title":"Clin. Microbiol. Rev."},{"key":"B34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrmicro3231","article-title":"The co-pathogenesis of influenza viruses with bacteria in the lung","volume":"12","author":"McCullers","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1086\/341462","article-title":"Lethal synergism between influenza virus and Streptococcus pneumoniae: characterization of a mouse model and the role of platelet-activating factor receptor","volume":"186","author":"McCullers","year":"2002","journal-title":"J. Infect. Diseases"},{"key":"B36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1345\/aph.10118","article-title":"Neuraminidase inhibitors: zanamivir and oseltamivir","volume":"35","author":"McNicholl","year":"2001","journal-title":"Ann. Pharmacother."},{"key":"B37","doi-asserted-by":"publisher","first-page":"6687","DOI":"10.1128\/JVI.00266-10","article-title":"Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus","volume":"84","author":"Miao","year":"2010","journal-title":"J. Virol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1086\/591708","article-title":"Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness","volume":"198","author":"Morens","year":"2008","journal-title":"J. Infect. Diseases"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1056\/NEJMra050740","article-title":"Neuraminidase inhibitors for influenza","volume":"353","author":"Moscona","year":"2005","journal-title":"New England J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","article-title":"Macrophage activation and polarization: nomenclature and experimental guidelines","volume":"41","author":"Murray","year":"2014","journal-title":"Immunity"},{"key":"B41","doi-asserted-by":"publisher","first-page":"jis726","DOI":"10.1093\/infdis\/jis726","article-title":"Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-10 influenza A (H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients","volume":"207","author":"Muthuri","year":"2012","journal-title":"J. Infect. Diseases."},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198504184.001.0001","volume-title":"Virus Dynamics: Mathematical Principles of Immunology and Virology: Mathematical Principles of Immunology and Virology","author":"Nowak","year":"2000"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e1002588","DOI":"10.1371\/journal.pcbi.1002588","article-title":"Modeling within-host dynamics of influenza virus infection including immune responses","volume":"8","author":"Pawelek","year":"2012","journal-title":"PLoS Comput. Biol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1177\/0091270008320317","article-title":"Population pharmacokinetics of oseltamivir when coadministered with probenecid","volume":"48","author":"Rayner","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3201\/eid1704.101429","article-title":"H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients","volume":"17","author":"Renaud","year":"2011","journal-title":"Emerg. Infect. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1172\/JCI35412","article-title":"Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice","volume":"119","author":"Shahangian","year":"2009","journal-title":"J. Clin. Invest."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1128\/AAC.00555-08","article-title":"Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008","volume":"52","author":"Sheu","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.4049\/jimmunol.0902772","article-title":"Influenza infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK cell responses in the lung","volume":"184","author":"Small","year":"2010","journal-title":"J. Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e1003238","DOI":"10.1371\/journal.ppat.1003238","article-title":"Kinetics of coinfection with influenza a virus and Streptococcus pneumoniae","volume":"9","author":"Smith","year":"2013","journal-title":"PLoS Pathog."},{"key":"B50","author":"Tamiflu (R)","year":"2009","journal-title":"Tamiflu (R) (oseltamivir phosphate) Capsules and for Oral Suspension"},{"key":"B51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3851\/IMP2744","article-title":"The effect of intravenous peramivir, compared with oral oseltamivir, on the outcome of post-influenza pneumococcal pneumonia in mice","volume":"20","author":"Tanaka","year":"2015","journal-title":"Antiv. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1086\/598483","article-title":"Sialic acid: a preventable signal for pneumococcal biofilm formation, colonization, and invasion of the host","volume":"199","author":"Trappetti","year":"2009","journal-title":"J. Infect. Diseases"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial","volume":"283","author":"Treanor","year":"2000","journal-title":"Jama"},{"key":"B54","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3934\/mbe.2010.7.171","article-title":"Modeling the interaction of cytotoxic T lymphocytes and influenza virus infected epithelial cells","volume":"7","author":"Tridane","year":"2010","journal-title":"Mathemat. Biosci. Eng."},{"key":"B55","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.drudis.2013.05.012","article-title":"Model-based drug discovery: implementation and impact","volume":"18","author":"Visser","year":"2013","journal-title":"Drug Discov. Today"},{"key":"B56","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1128\/AAC.00588-08","article-title":"Pharmacokinetics of high-dose oseltamivir in healthy volunteers","volume":"53","author":"Wattanagoon","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"B57","article-title":"Influenza (seasonal). Fact sheet no. 211.","author":"World Health Organization","year":"2009a","journal-title":"World Health Organization"},{"key":"B58","volume-title":"WHO Guidelines for Pharmacological Management of Pandemic (H1N1) 2009: Influenza and Other Influenza Viruses","author":"World Health Organization","year":"2009b"},{"key":"B59","first-page":"37","article-title":"Update on oseltamivir-resistant influenza A (H1N1) 2009 influenza virus: January 2010","volume-title":"Wkly Epidemiol Rec.","author":"World Health Organization","year":"2010"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T16:13:41Z","timestamp":1718640821000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/Article\/10.3389\/fcimb.2016.00060\/abstract"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,14]]},"references-count":59,"URL":"https:\/\/doi.org\/10.3389\/fcimb.2016.00060","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,14]]}}}